UNSPSC 51132225: Acetaminophen/tramadol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132225 Acetaminophen/tramadol is a Commodity code that encompasses pharmaceutical pain-management products procured by state health agencies, county health systems, and cooperative purchasing alliances for community health programs, pharmacy benefit initiatives, and institutional distribution. State and local governments buy acetaminophen and tramadol primarily as components of broader pharmaceutical procurement programs, often bundled with other generic medications, OTC products, or ancillary health supplies. Recent solicitations show issuing bodies ranging from county-level community health departments to state health and human services commissions and multistate cooperative purchasing consortia, all sourcing through authorized pharmaceutical wholesalers or direct manufacturer relationships to support public health delivery, employee benefit programs, and emergency response capabilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs and vendor capacity for negotiated net pricing models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026; vendors must work through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification.